The prospective, multi-center phase 3 PRIMARY randomized trial tested the additive diagnostic value of PSMA PET imaging in high-risk men with negative or equivocal MRI in the diagnosis of significant ...

For its 2nd anniversary, Callisto DataHub offers free annotated datasets of 50 suspected lung cancer X-rays and 50 ...

Lucida Medical has raised £8.7m to power its ‘same-day’ cancer diagnosis. IW Capital has invested in the Cambridge healthtech ...

Lucida’s software is designed to identify prostate cancer ‘within minutes’ and overcome diagnosis delays associated with ...

AI enhanced MRI improves prostate cancer detection accuracy, outperforming traditional methods and supporting better diagnosis.

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

MRI-based prostate cancer screening of the general population does not increase detection of clinically significant prostate cancer, but it does improve the benefit-vs-harm profile of PSA testing ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...